JP2009506043A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009506043A5 JP2009506043A5 JP2008528076A JP2008528076A JP2009506043A5 JP 2009506043 A5 JP2009506043 A5 JP 2009506043A5 JP 2008528076 A JP2008528076 A JP 2008528076A JP 2008528076 A JP2008528076 A JP 2008528076A JP 2009506043 A5 JP2009506043 A5 JP 2009506043A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- diabetes
- obesity
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 208000008589 Obesity Diseases 0.000 claims 7
- 235000020824 obesity Nutrition 0.000 claims 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000002249 Diabetes Complications Diseases 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical group 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000011661 metabolic syndrome X Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70979805P | 2005-08-22 | 2005-08-22 | |
| US60/709,798 | 2005-08-22 | ||
| US80853306P | 2006-05-26 | 2006-05-26 | |
| US60/808,533 | 2006-05-26 | ||
| PCT/US2006/032788 WO2007024863A2 (en) | 2005-08-22 | 2006-08-22 | Methods and formulations for modulating lyn kinase activity and treating related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009506043A JP2009506043A (ja) | 2009-02-12 |
| JP2009506043A5 true JP2009506043A5 (cg-RX-API-DMAC10.html) | 2009-09-24 |
| JP5113752B2 JP5113752B2 (ja) | 2013-01-09 |
Family
ID=37635750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008528076A Active JP5113752B2 (ja) | 2005-08-22 | 2006-08-22 | Ｌｙｎキナーゼの活性を調節し、関連する疾患を治療するための方法および製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US7776870B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1924262B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5113752B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR101452518B1 (cg-RX-API-DMAC10.html) |
| AT (1) | ATE533488T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2006283211B2 (cg-RX-API-DMAC10.html) |
| BR (1) | BRPI0615046C1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2620065C (cg-RX-API-DMAC10.html) |
| IL (1) | IL189603A0 (cg-RX-API-DMAC10.html) |
| NZ (1) | NZ565955A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2007024863A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1924262B1 (en) | 2005-08-22 | 2011-11-16 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating lyn kinase activity and treating related disorders |
| CA2678813A1 (en) * | 2007-02-20 | 2008-08-28 | Melior Pharmaceuticals I, Inc. | Methods of identifying activators of lyn kinase |
| WO2008147687A1 (en) * | 2007-05-21 | 2008-12-04 | Mayo Foundation For Medical Education And Research | Treating pancreatitis |
| US20100197710A1 (en) * | 2007-07-23 | 2010-08-05 | Melior Pharmaceuticals I, Inc. | Methods Of Activating IRS-1 And AKT |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| AU2012352480A1 (en) * | 2011-12-12 | 2014-07-17 | Melior Pharmaceuticals I, Inc. | Treatment of type I and type II diabetes |
| US9687486B2 (en) * | 2012-12-20 | 2017-06-27 | The Trustees Of Columbia University In The City Of New York | Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator |
| JOP20200093A1 (ar) | 2015-01-09 | 2017-06-16 | Kyowa Kirin Co Ltd | طريقة لإنتاج مشتق ثيازول |
| CN110785170B (zh) | 2017-04-10 | 2023-03-28 | 梅里奥尔医药I公司 | 脂肪细胞的治疗 |
| US20210106581A1 (en) | 2018-02-21 | 2021-04-15 | Melior Pharmaceuticals I, Inc. | Treatment Of Liver Diseases |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| BE790125A (fr) | 1971-10-29 | 1973-04-16 | Pfizer | Nouvelles pyrimidinones et nouvelles hydroxypyrimidines |
| US3922345A (en) | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| US4080454A (en) | 1976-07-16 | 1978-03-21 | Pfizer Inc. | 5-M-Tolyloxyuracil, anti-ulcer agent |
| US4612376A (en) | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| GB9214720D0 (en) | 1992-07-10 | 1992-08-19 | Wellcome Found | Enzyme inhibitors |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5476855A (en) | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| US6900304B2 (en) | 1996-01-31 | 2005-05-31 | The Regents Of The University Of California | Emission ratiometric indicators of phosphorylation |
| US20020019346A1 (en) | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6410255B1 (en) | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
| US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
| GB0104422D0 (en) | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| ES2290743T3 (es) | 2003-04-30 | 2008-02-16 | The Institutes For Pharmaceutical Discovery, Llc | Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas. |
| US20050208054A1 (en) | 2003-12-09 | 2005-09-22 | University Of Massachusetts | Methods of identifying insulin response modulators and uses therefor |
| EP1541694A1 (en) | 2003-12-12 | 2005-06-15 | Sirenade Pharmaceuticals AG | Methods of identifying, selecting and/or characterizing compounds which modulate the activity of a Src family kinase |
| US20060035302A1 (en) | 2004-06-21 | 2006-02-16 | Applera Corporation | Kinase substrates with multiple phosphorylation sites |
| EP1827434B1 (en) | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
| WO2007016975A1 (en) | 2005-07-29 | 2007-02-15 | F. Hoffmann-La Roche Ag | Kinase and phosphatase assays based on fret |
| US20070025953A1 (en) | 2005-07-27 | 2007-02-01 | Jones Michael R | Co-therapy for diabetic conditions |
| EP1924262B1 (en) | 2005-08-22 | 2011-11-16 | Melior Pharmaceuticals I, Inc. | Methods and formulations for modulating lyn kinase activity and treating related disorders |
| PL1924264T3 (pl) | 2005-09-01 | 2014-03-31 | Hoffmann La Roche | Diaminopirymidyny jako modulatory P2X<sub>3</sub> I P2X<sub>2/3</sub> |
| KR100881728B1 (ko) | 2007-05-04 | 2009-02-06 | 주식회사 하이닉스반도체 | 루테늄전극을 구비한 반도체소자 및 그 제조 방법 |
| US20100197710A1 (en) | 2007-07-23 | 2010-08-05 | Melior Pharmaceuticals I, Inc. | Methods Of Activating IRS-1 And AKT |
| US8552184B2 (en) | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| US9278134B2 (en) | 2008-12-29 | 2016-03-08 | The Board Of Trustees Of The University Of Alabama | Dual functioning ionic liquids and salts thereof |
| WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| EP3943092B1 (en) | 2014-02-24 | 2024-11-13 | Energesis Pharmaceuticals Inc. | Compositions for use in inducing differentiation of human brown adipocyte progenitors |
| CN110785170B (zh) * | 2017-04-10 | 2023-03-28 | 梅里奥尔医药I公司 | 脂肪细胞的治疗 |
-
2006
- 2006-08-22 EP EP06813647A patent/EP1924262B1/en active Active
- 2006-08-22 KR KR1020087006891A patent/KR101452518B1/ko active Active
- 2006-08-22 CA CA2620065A patent/CA2620065C/en active Active
- 2006-08-22 KR KR1020147016962A patent/KR101577554B1/ko active Active
- 2006-08-22 WO PCT/US2006/032788 patent/WO2007024863A2/en not_active Ceased
- 2006-08-22 BR BRPI0615046A patent/BRPI0615046C1/pt active IP Right Grant
- 2006-08-22 NZ NZ565955A patent/NZ565955A/en unknown
- 2006-08-22 AU AU2006283211A patent/AU2006283211B2/en active Active
- 2006-08-22 AT AT06813647T patent/ATE533488T1/de active
- 2006-08-22 JP JP2008528076A patent/JP5113752B2/ja active Active
- 2006-08-22 US US11/507,652 patent/US7776870B2/en active Active
-
2008
- 2008-02-19 IL IL189603A patent/IL189603A0/en active IP Right Grant
-
2010
- 2010-07-15 US US12/837,067 patent/US8343985B2/en active Active
-
2012
- 2012-11-30 US US13/690,548 patent/US8835448B2/en active Active
-
2014
- 2014-02-18 US US14/182,380 patent/US9216959B2/en active Active
-
2015
- 2015-11-13 US US14/941,473 patent/US9763945B2/en active Active
-
2017
- 2017-08-23 US US15/684,130 patent/US10251883B2/en active Active
-
2019
- 2019-02-27 US US16/286,976 patent/US11033548B2/en active Active
-
2021
- 2021-05-07 US US17/314,543 patent/US12070461B2/en active Active